RxDoctor Payments Data

Ruben Ayala, MD

Internal Medicine · Miami, FLNPI 1326012303

Payments from drug & device makers

$24,219in general payments, 2019–2025

Across 1,198 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$2K
  • Sanofi-aventis U.S. LLC$2K
  • Amgen$2K
  • GSK$2K
  • plus $13K from 53 others

What the payments were for

  • Food & beverage$23,90299%
  • Education$3171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk129$2,428
AbbVie(2 entities)183$2,169
AstraZeneca91$1,923
Sanofi-aventis U.S. LLC62$1,730
Amgen(2 entities)74$1,517
GSK78$1,510
Lilly USA, LLC54$966
Novartis42$917
Boehringer Ingelheim51$910
Esperion Therapeutics, Inc.19$875
Shield Therapeutics Inc13$688
Astellas Pharma US Inc30$672
Amarin Pharma, Inc.38$659
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC43$645
Bayer22$570
Abbott14$550
Johnson & Johnson30$433
Pfizer23$419
Inspire Medical Systems, Inc.1$383
Exact Sciences16$345
Radius Health, Inc.12$336
Phathom Pharmaceuticals, Inc.9$291
Merck15$285
Sunovion Pharmaceuticals Inc.14$230
Otsuka America Pharmaceutical, Inc.9$213
E.r. Squibb & Sons, L.L.C.10$182
Kowa Pharmaceuticals America, Inc.10$180
Azurity Pharmaceuticals, Inc.7$163
Eisai Inc.8$154
Nestle Healthcare Nutrition Inc.17$147
Optinose US, Inc.8$146
Biogen3$145
Impulse Dynamics (USA) Inc.2$143
Insulet Corporation6$119
Ardelyx, Inc.6$119
Boston Scientific3$118
Insmed, Inc.5$96
Corcept Therapeutics5$96
Smith+Nephew2$88
Ironwood Pharmaceuticals, Inc4$85
Dexcom, Inc.3$56
Evoke Pharma, Inc.3$54
Scilex Pharmaceuticals Inc.2$46
Lexicon Pharmaceuticals, Inc.2$39
Regeneron Healthcare Solutions, Inc.2$37
Cipher Pharmaceuticals US LLC1$36
Sumitomo Pharma America, Inc.2$36
Arbor Pharmaceuticals, Inc.2$34
Mannkind Corporation2$33
Nabriva Therapeutics, PLC2$32
Aimmune Therapeutics, Inc.1$27
Ultragenyx Pharmaceutical Inc.1$22
Xeris Pharmaceuticals, Inc.1$22
Biohaven Pharmaceutical Holding Company Ltd.1$20
IBSA Pharma Inc.1$19
Gilead1$19
Axsome Therapeutics, Inc.1$15
Hikma Pharmaceuticals USA1$14
Avanir Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,219 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$123,260
Medicare patients
255
Services billed
1,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan194$250,149
OzempicSemaglutide169$246,306
MounjaroTirzepatide176$226,630
Xigduo XrDapaglifloz Propaned/Metformin180$202,875
EliquisApixaban155$175,475
Trelegy ElliptaFluticasone/Umeclidin/Vilanter144$170,017
ProliaDenosumab87$148,588
Synjardy XrEmpagliflozin/Metformin Hcl91$130,358
FarxigaDapagliflozin Propanediol89$120,223
ZenpepLipase/Protease/Amylase18$115,865
TrulicityDulaglutide48$90,966
JardianceEmpagliflozin59$78,264
CreonLipase/Protease/Amylase15$76,814
LinzessLinaclotide58$73,199
VascepaIcosapent Ethyl117$70,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$966$317,596224 claims
Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Tradjenta, Jentadueto$910$274,891218 claims
NovartisEntresto$917$250,149194 claims
Novo NordiskOzempic$2,428$246,306169 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,510$190,275172 claims
PfizerEliquis$419$175,475155 claims
AbbVieCreon, Linzess, Synthroid$2,169$166,138234 claims
AmgenProlia$1,517$148,58887 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$1,923$146,760119 claims
Aimmune Therapeutics, Inc.Zenpep$27$115,86518 claims
Johnson & JohnsonXarelto$433$59,51451 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$1,730$58,33750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →